Skip to main content
TipRanks
Go Ultimate75% OFF

Suheung Co. Ltd. (008490) AI Stock Analysis

KR:008490

Suheung Co. Ltd.

(Korea Exchange:008490)

Select Model
Rating:71Outperform
Price Target:KRW 17,757.00â–²(10.50% Upside)
Action:reiterated
Date:11/14/26

Strong financial performance and attractive valuation are the main positives; weak technical momentum caps the overall score.

Positive Factors
Revenue GrowthTTM revenue growth of 43.4% indicates a substantial demand or recovery upswing after the 2023 decline. If maintained, this expands the company’s scale across pharmaceutical and healthcare markets and can improve operating leverage, although profitability quality still requires monitoring.
Negative Factors
Margin CompressionNet margin fell to 4.8% TTM from 6.0% in 2025, while net income declined despite much higher revenue. This shows that recent growth has not translated proportionally into earnings and leaves the business more exposed to cost pressure or below-the-line weakness.

Suheung Co. Ltd. (008490) vs. SPDR S&P 500 ETF (SPY)

-40%-30%-20%-10%0%10%20%30%KR:008490-30.28%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
KRW 178.96B
Dividend Yield
3.11%
Average Volume (3M)
20.13K
Price to Earnings (P/E)
4.8
Beta (1Y)
0.12
Revenue Growth
9.19%
EPS Growth
-6.51%
Country
KR
Employees
769
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - Specialty & Generic

Suheung Co. Ltd. Business Overview & Revenue Model

Company Description

Suheung Co., Ltd. specializes in the production and provision of empty hard capsules, which are primarily utilized within the pharmaceutical and nutraceutical industries. The company further diversifies its business by offering comprehensive contract...

Suheung Co. Ltd. Financial Statement Overview

Summary

Strong revenue growth of 43.4% to 769B TTM and net margin recovery to 4.8%, paired with improved balance sheet (D/E 0.75) and positive cash flow.

Income Statement

76Positive

Balance Sheet

81Very Positive

Cash Flow

65Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue769.23B722.31B653.26B594.57B634.97B596.73B
Gross Profit131.04B123.32B103.23B99.03B137.28B126.23B
EBITDA72.68B91.23B73.47B77.16B98.73B115.01B
Net Income36.95B43.49B18.28B6.12B33.98B53.69B
Balance Sheet
Total Assets1.07T1.06T1.02T993.74B926.42B809.95B
Cash, Cash Equivalents and Short-Term Investments75.56B58.68B49.15B48.42B58.32B34.18B
Total Debt380.83B435.08B449.36B467.86B404.68B342.99B
Total Liabilities498.99B520.12B509.92B516.67B456.69B380.09B
Stockholders Equity509.80B488.68B454.68B425.67B421.34B387.76B
Cash Flow
Free Cash Flow29.58B35.98B17.46B-41.77B-11.27B28.64B
Operating Cash Flow83.29B81.57B56.16B10.49B52.91B66.85B
Investing Cash Flow-73.79B-49.93B-18.08B-70.17B-93.45B-56.79B
Financing Cash Flow-8.83B-20.48B-41.10B56.99B50.52B-23.23B

Suheung Co. Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price16070.00

Price Trends

50DMA19425.20Negative
100DMA20305.50Negative
200DMA20344.10Negative

Market Momentum

MACD-690.78Positive
RSI24.51Positive
STOCH24.62Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:008490, the sentiment is Negative. The current price of 16070.00 is below the 20-day moving average (MA) of 17945.00, below the 50-day MA of 19425.20, and below the 200-day MA of 20344.10, indicating a bearish trend. The MACD of -690.78 indicates Positive momentum. The RSI at 24.51 is Positive, neither overbought nor oversold. The STOCH value of 24.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:008490.

Suheung Co. Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

KR:008490 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
KR:033270KR:03327071OutperformKRW 227.50B4.38―3.91%0.85%25.23%
KR:008490KR:00849071OutperformKRW 193.47B4.84―3.11%9.19%-6.51%
KR:005500KR:00550066NeutralKRW 232.23B10.57―4.05%0.28%16.80%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
KR:004310KR:00431052NeutralKRW 200.96B53.87―0.46%11.35%204.54%
KR:009290KR:00929052NeutralKRW 297.76B24.73―1.59%5.20%-65.65%
KR:003520KR:00352040UnderperformKRW 141.56B-18.48――1.83%-860.41%

* General Sector Average

Performance Comparison

0%100%200%KR:008490KR:003520KR:004310KR:005500KR:009290KR:033270Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
KR:008490 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
KR:008490Suheung Co. Ltd.16070.00-8640.26-34.97%
KR:003520YUNGJIN PHARM. CO. LTD795.00-1245.00-61.03%
KR:004310Hyundai Pharmaceutical Co., Ltd.6510.002734.5372.43%
KR:005500Samjin Pharmaceutical Co., Ltd.19760.00483.012.51%
KR:009290Kwang Dong Pharmaceutical Co., Ltd.6270.00348.935.89%
KR:033270KOREA UNITED PHARM, INC.15590.00-3735.87-19.33%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 14, 2026